Study shows paxlovid can safely be used to reduce risk of severe COVID in people who are pregnant jamanetworkopen
Race and ethnicity were classified by self-report in the electronic medical record and were collected to characterize the differences in socioeconomic factors associated with access to care. Age was defined as the age when the patient was treated with nirmatrelvir and ritonavir. Vaccination status was defined as having had no vaccination, having received the initial vaccination series, or having received the initial vaccination series with 1 or 2 additional boosters.
All patients were either treated for COVID-19 as outpatients or were treated while hospitalized for reasons other than COVID-19. Thirty-seven prescriptions were written by obstetricians and gynecologists, and 10 were written by midlevel practitioners . Twelve prescriptions were filled in May 2022, 17 in June 2022, 12 in July 2022, and 6 in August 2022. Viral sequencing data were available for 5 patients whose testing was performed within the Johns Hopkins Health System.
Two patients were hospitalized during pregnancy after treatment with nirmatrelvir and ritonavir: 1 for vomiting and dehydration in the setting of preexisting hyperemesis gravidarum and 1 for persistent cough in the context of sickle cell crisis; this patient was identified as having placenta accreta and experienced postpartum hemorrhage. Two patients discontinued the medication before completing treatment due to adverse effects. Three patients developed gestational hypertension.
Only 2 patients discontinued nirmatrelvir and ritonavir due to adverse effects, and no complications were associated with the drug. This finding was replicated in another descriptive study from the University of Connecticut of 7 pregnant patients treated with nirmatrelvir and ritonavir who all experienced symptomatic improvement and no adverse pregnancy outcomes.In accordance with our findings, 85.
The CDC and IDSA outpatient treatment guidelines include pregnant patients among populations at higher risk for developing severe COVID-19 and who are eligible to use nirmatrelvir and ritonavir.
Danmark Seneste Nyt, Danmark Overskrifter
Similar News:Du kan også læse nyheder, der ligner denne, som vi har indsamlet fra andre nyhedskilder.
Nanoparticles displaying SARS-CoV-1 and SARS-CoV-2 spikes induce broad antibody responses in animal modelNanoparticles displaying SARS-CoV-1 and SARS-CoV-2 spikes induce broad antibody responses in animal model Antibody Nanoparticles SARS SARSCoV2 Coronavirus Disease COVID iScience_CP UW WeillCornell UvA_Amsterdam scrippsresearch
Læs mere »
Cryo-electron tomography helps visualize platelet deformation due to SARS-CoV-2 spike proteinResearchers used cellular cryo-electron tomography (cryo-ET) to demonstrate the role of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein in coronavirus disease 2019 (COVID-19)-triggered severe coagulopathies.
Læs mere »
Molecular and cellular similarities identified in the brains of SARS-CoV-2 and Alzheimer's disease patientsResearchers evaluated neuro-pathophysiological consequences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, especially the post-acute sequelae of SARS-CoV-2 (PASC) in Alzheimer’s disease (AD) patients.
Læs mere »
Isolated monoclonal antibodies targeting SARS-CoV-2 S1/S2 cleavage effective against Delta and OmicronIsolated monoclonal antibodies targeting SARS-CoV-2 S1/S2 cleavage effective against Delta and Omicron Antibodies Coronavirus Disease COVID Delta Omicron SARSCoV2 SciReports UTokyo_News OsakaU_Research gunma_uni_ad
Læs mere »
How SARS-CoV-2 immune responses vary by population due to environmental and genetic factorsHow SARS-CoV-2 immune responses vary by population due to environmental and genetic factors Coronavirus Disease COVID Genetics Environmental SARSCoV2 biorxivpreprint HKUniversity RockefellerUniv ugent waynestate institutpasteur
Læs mere »
Small CDC study looks at SARS-CoV-2 viral shedding in vaccinated and unvaccinatedA new Centers for Disease Control and Prevention (CDC) study published in the Vaccine journal aimed to analyze the viral shedding and conversion timeline of SARS-CoV-2 infected people from exposure to infection and onset of symptoms during a period of Delta outbreak in a federal prison in Texas.
Læs mere »